Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the foundational identification statements (drug contains semaglutide; semaglutide is a GLP-1 receptor agonist) are supported by the provided label sections. Most efficacy/safety/combination-use claims are not supported by the provided label excerpts, and several “risk/side effect” claims are not verifiably grounded in the missing warnings/adverse reactions sections.
Category Scores
Accurate Statements
Wegovy is a prescription medication containing semaglutide.
11 DESCRIPTION
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
11 DESCRIPTION
Unsupported Statements
Wegovy is primarily used to manage type 2 diabetes.
Not supported by the provided 1 INDICATIONS AND USAGE excerpts; no type 2 diabetes indication is provided in the available text.
Wegovy has been shown to improve glycemic control.
No glycemic control language is provided in the available label sections (only 1 INDICATIONS AND USAGE and 11 DESCRIPTION are provided).
Wegovy has been shown to reduce body weight.
Weight reduction is generally supported by the available 1 INDICATIONS AND USAGE, but the claim that it has been “shown” is not verifiable because 14 CLINICAL STUDIES text is not provided.
Wegovy has been shown to lower blood pressure.
No blood pressure outcome language is provided in the available label sections.
Wegovy received FDA approval in 2021.
No FDA approval date information is provided in the available label sections.
Semaglutide has been found to improve insulin sensitivity.
No insulin sensitivity language is provided in the available label sections.
Semaglutide has been found to reduce insulin resistance.
No insulin resistance language is provided in the available label sections.
In phase 3 clinical trials, Wegovy demonstrated a significant increase in insulin sensitivity.
14 CLINICAL STUDIES is not provided; no phase 3 insulin-sensitivity trial results are available in the excerpts.
In phase 3 clinical trials, insulin sensitivity was measured by hemoglobin A1c (HbA1c) levels and insulin levels.
No trial measurement details are provided in the available label excerpts.
Semaglutide is thought to enhance glucose uptake in muscles.
No mechanistic statements about muscle glucose uptake are provided in the available label excerpts.
Semaglutide is thought to reduce hepatic glucose production.
No mechanistic statements about hepatic glucose production are provided in the available label excerpts.
By improving insulin sensitivity and reducing insulin resistance, Wegovy may help prevent the onset of type 2 diabetes in high-risk individuals.
No diabetes prevention indication or supporting language is provided in the available 1 INDICATIONS AND USAGE excerpts.
Wegovy's weight reduction effects could contribute to mitigation of insulin resistance in obese patients.
No insulin-resistance mitigation language is provided in the available 1 INDICATIONS AND USAGE excerpts.
Wegovy may be used in combination with metformin to manage type 2 diabetes and improve insulin sensitivity.
No type 2 diabetes indication and no combination-use language with metformin is provided in the available label excerpts.
Wegovy may be used in combination with sulfonylureas to manage type 2 diabetes and improve insulin sensitivity.
No type 2 diabetes indication and no combination-use language with sulfonylureas is provided in the available label excerpts.
Wegovy may be used in combination with pioglitazone to manage type 2 diabetes and improve insulin sensitivity.
No type 2 diabetes indication and no combination-use language with pioglitazone is provided in the available label excerpts.
Common side effects of Wegovy include nausea.
No adverse reaction frequency/list is provided in the available sections (only a specific severe GI adverse reaction discussion in 5.6 is included).
Common side effects of Wegovy include vomiting.
No adverse reaction frequency/list is provided in the available sections.
Common side effects of Wegovy include diarrhea.
No adverse reaction frequency/list is provided in the available sections.
Common side effects of Wegovy include injection site reactions.
No adverse reaction list supporting injection site reactions is provided in the available sections.
Wegovy may increase the risk of pancreatic cancer.
The provided excerpts do not include boxed warning/warnings or an adverse-reaction section establishing this risk.
Wegovy may increase the risk of thyroid C-cell tumors.
The provided excerpts do not include boxed warning/warnings or an adverse-reaction section establishing this risk.
Wegovy may increase the risk of allergic reactions.
The provided excerpts do not include boxed warning/warnings or an adverse-reaction section establishing this risk.
Contradictions
Important Omissions
Dose and administration details (including titration/starting dose) for WEGOVY injection/tablets.
Importance:
Moderate
Boxed warning, contraindications, detailed warnings/precautions, adverse reaction list, and drug interaction specifics from the label.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claimed safety risks and “common side effects” are not supported by the provided label excerpts (warnings/adverse reactions sections are not included). This reduces the audit’s ability to ensure label-consistent safety communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Most efficacy and safety claims are not supported by the provided label excerpts, and diabetes-related/combination-use and specific risk claims cannot be verified from the supplied sections.
Suggested Improvement
Restrict claims to label-supported content from the provided excerpts (e.g., semaglutide/GLP-1 identity; weight reduction and CV risk-reduction indications in 1 INDICATIONS AND USAGE). For safety, use the actual 4 CONTRAINDICATIONS, 5 WARNINGS AND PRECAUTIONS (boxed warnings), and 6 ADVERSE REACTIONS text before making risk/side-effect statements.